enrollment

September 29, 2020September 29, 2020

Aptinyx Reopens Enrollment in Phase 2 Study of NYX-2925 for Chronic Pain

News

Enrollment has resumed for Aptinyx‘s Phase 2 clinical trial of NYX-2925, an oral small molecule designed to treat chronic pain in adults with fibromyalgia, the company announced. The study (NCT04147858) is ... Read more

July 7, 2020July 7, 2020

Bedtime Fibromyalgia Therapy TNX-102 SL Sees Faster-than-expected Trial Enrollment

News

Enrollment in the RELIEF Phase 3 trial assessing TNX-102 SL (sublingual cyclobenzaprine) as a nighttime treatment for pain and disturbed sleep due to fibromyalgia has been faster than expected, according ... Read more

April 30, 2020April 30, 2020

Phase 3 Trial of Bedtime Treatment, TNX-102 SL, Reaches Half Enrollment

News

The RELIEF Phase 3 trial assessing the safety and efficacy of TNX-102 SL (sublingual cyclobenzaprine) as a nighttime treatment of pain and disturbed sleep due to fibromyalgia has reached half of its ... Read more

April 2, 2020April 2, 2020

Pandemic Prompts Pause of Patient Enrollment in Fibromyalgia Trial of NYK-2925

News

In response to the COVID-19 pandemic, Aptinyx has temporarily suspended enrollment in its ongoing Phase 2b clinical trial investigating NYX-2925 in women with fibromyalgia. The company, however, has taken measures to make sure ... Read more

November 15, 2019November 15, 2019

New Phase 2 Trial to Test NYX-2925 as Potential Fibromyalgia Therapy

News

A new Phase 2 clinical trial will continue to assess the safety and effectiveness of the non-opioid small molecule candidate therapy NYX-2925, developed by Aptinyx, in fibromyalgia patients. NYX-2925 is an oral ... Read more